Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07629167 · ClinicalTrials.gov registry record · Phase 2
Isotretinoin vs. Doxycycline for Acneiform Rash in Patients Receiving Drugs That Target the MAPK Pathway
A Phase 2 study, sponsored by University of California, San Francisco.
- Not yet
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT07629167 is a Phase 2 study that has not yet begun recruiting, run by University of California, San Francisco. The registered enrollment target is 50 participants.
The verdict
NCT07629167, a Phase 2 study, has not yet begun recruiting, sponsored by University of California, San Francisco.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
A phase 2 study testing the efficacy of isotretinoin versus doxycycline in treating participants who develop a acneiform rash caused by standard of care, tumor-directed therapies targeting the mitogenactivated protein kinase (MAPK) pathway.
Interventions
- BEHAVIORAL Questionnaires
- DRUG Doxycycline
- DRUG Isotretinoin
- PROCEDURE Blood specimen collection
- OTHER Photographs of Rash
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2026-08-30 |
| Est. Completion | 2030-03-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07629167
The ClinicalTrials.gov registry entry for NCT07629167 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Questionnaires is the first listed.
NCT07629167 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07629167 about?
NCT07629167 is a clinical study titled "Isotretinoin vs. Doxycycline for Acneiform Rash in Patients Receiving Drugs That Target the MAPK Pathway". A phase 2 study testing the efficacy of isotretinoin versus doxycycline in treating participants who develop a acneiform rash caused by standard of care, tumor-directed therapies targeting the mitogenactivated protein kinase (MAPK) pathway.
What is the current status of trial NCT07629167?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2026-08-30. Estimated completion is 2030-03-30.
What interventions are being tested in trial NCT07629167?
The interventions under investigation include: Questionnaires (BEHAVIORAL), Doxycycline (DRUG), Isotretinoin (DRUG), Blood specimen collection (PROCEDURE), Photographs of Rash (OTHER).
Who is sponsoring clinical trial NCT07629167?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.